Searchable abstracts of presentations at key conferences in endocrinology

ea0063p775 | Thyroid 2 | ECE2019

Clinical profile and treatment modalities of patients presenting with hyperthyroidism in a tertiary endocrine center in nepal

Joshi Ansumali , Yonzon Priyadarshini

Data regarding hyperthyroidism is lacking in Nepal. We did a retrospective analysis of clinical profile and treatment modalities of hyperthyroidism patients in our center.Methodology: Retrospective data of 132 hyperthyroidism patients between March 2013 and April 2014 at Kathmandu Diabetes and Thyroid Center were analyzed. These patients’ records were followed up for one year.Results: Hyperthyroidism was common in females (73....

ea0063p776 | Thyroid 2 | ECE2019

Community based study of thyroid disorder prevalence in Nepal

Joshi Ansumali , Yonzon Priyadarshini

Nepal seems to have high thyroid disorder prevalence but there has been no prevalence studies done so far in general population. We do have a few hospital based prevalence studies of hypothyroidism in Nepal. Our study aims to find the prevalence of thyroid disorders in general population in Nepal.Methods: We did thyroid function tests of the general population through screening camps in different parts of Nepal. We screened people from 7 places in 5 dist...

ea0056ep110 | Pituitary and Neuroendocrinology | ECE2018

Clinical profile of patients with hyperprolactinemia: a study based on nepalese population

Joshi Ansumali , Yonzon Priyadarshini

Background: Hyperprolactinemia is a common endocrine disorder. Yet, data on clinical profile of Nepalese patients with hyperprolactinemia is missing. The aim of this study was to assess the clinical profile of Nepalese patients with hyperprolactinemia.Methodology: Retrospective clinic based study conducted at the endocrine centre Kathmandu Diabetes and Thyroid Center, Lalitpur, Nepal, in which data was collected from the patient record files of the subje...

ea0070ep468 | Thyroid | ECE2020

Etiological profile of hypothyroidism in Nepalese patients

Joshi Ansumali , Yonzon Priyadarshini , Tamang Sabeena

Background: Hypothyroidism is a common endocrine disorder. Common causes are autoimmune disease such as Hashimoto’ thyroiditis, surgical removal of the thyroid, drug induced and radioactive iodine (RAI) ablation.Aim: The aim of our study was to determine the etiology of hypothyroidism in Nepalese patients.Method: This is a retrospective study conducted in our opd from May 2015 to April 2019 in which data was collected from th...

ea0070ep492 | Thyroid | ECE2020

Clinical profile of patients with solitary thyroid nodules attending tertiary endocrine centre in Kathmandu, Nepal

Joshi Ansumali , Yonzon Priyadarshini , Rai Pavitra

Background: Thyroid nodules are common with annual increasing trends worldwide. 5% to 15% of the thyroid nodules is thyroid cancer. The prevalence of thyroid nodule is 3%–7% prevalence by palpation and 19%–67% by high resolution ultrasound. Thyroid nodules are more prevalent in women and older age group. More than 95% of all thyroid nodules are benign.Aim: The aim of this study is to assess the clinical profile of patients with solitary thyro...

ea0070ep494 | Thyroid | ECE2020

Clinical profile of thyroid cancer patients attending a tertiary endocrine center in Nepal

Joshi Ansumali , Yonzon Priyadarshini , Sharma Thuma

Background: Thyroid cancer is the most common malignant disease of the endocrine system. Thyroid cancer represents above 1% of all malignancies. There is a paucity of data on thyroid cancer in Nepalese patients.Aim: The aim of this study is to explore clinical profile of thyroid cancer patients diagnosed and managed in our center.Methods: A total of 70 patients with thyroid cancer were included in the sample from March 2013 to Dece...

ea0070aep490 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Clinical and safety profile of empagliflozin in nepalese type 2 diabetes patients

Joshi Ansumali , Yonzon Priyadarshini , Thapa Luna , Karki Ritika

Background: The only available SGLT2 inhibitor in Nepal till date is empagliflozin. Empaglilozin has shown to be cardioprotective and renoprotective in randomized trials. It has shown to reduce some weight. There is a lack of data of SGLT2 inhibitors in Nepalese Type 2 diabetes patients.Aim: The aim of our study is to determine the effects of empagliflozin in glycemic control in terms of HbA1C reduction, weight, improvement in eGFR and side effect profil...